8-K: CorMedix Reports First Quarter 2024 Results and Provides Business Update

CorMedix announced its first quarter 2024 financial results, highlighted by the commercial launch of DefenCath and progress towards outpatient availability.

Summary

• CorMedix reported a net loss of $14.5 million, or $0.25 per share, for the first quarter of 2024, compared to a net loss of $10.6 million, or $0.24 per share, in the same period of 2023.
• The increased loss was primarily due to a rise in operating expenses, which reached $15.9 million, a 44% increase year-over-year.
• Selling, general, and administrative expenses saw a significant increase of 98%, reaching $15.0 million, driven by the hiring of sales, medical affairs, and marketing personnel.
• Research and development expenses decreased by approximately 75% due to the shift of certain costs to SG&A following FDA approval of DefenCath.
• The company's cash and short-term investments totaled $58.6 million as of March 31, 2024.
• CorMedix commenced the commercial launch of DefenCath in the inpatient setting on April 15, 2024, and is on track for an outpatient launch in July 2024.
• The company secured a 5-year commercial supply contract with ARC Dialysis, LLC.
• The company received a Transitional Drug Add-On Payment (TDAPA) for DefenCath, effective July 1, 2024, which provides additional reimbursement for five years.
• CorMedix submitted a supplement to the FDA to add Siegfried Hameln as an alternate manufacturing site, with approval expected by the end of 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the commercial launch of DefenCath and the receipt of TDAPA, but is tempered by the increased net loss and operating expenses.

Positives

• The commercial launch of DefenCath in the inpatient setting has commenced.
• The company is on track for the outpatient launch of DefenCath in July 2024.
• The company secured a 5-year commercial supply contract with ARC Dialysis, LLC.
• DefenCath received a Transitional Drug Add-On Payment (TDAPA), which will provide additional reimbursement for five years.
• The company has $58.6 million in cash and short-term investments, excluding restricted cash.
• The company has submitted a supplement to the NDA to add an alternate manufacturing site.

Negatives

• The company reported a net loss of $14.5 million for the first quarter of 2024, an increase from the $10.6 million loss in the same period of 2023.
• Operating expenses increased by 44% year-over-year, reaching $15.9 million.
• Selling, general, and administrative expenses increased by 98% to $15.0 million.
• The company's cash and cash equivalents decreased from $43.8 million to $35.4 million during the quarter.

Risks

• The company is experiencing increased operating expenses, particularly in selling, general, and administrative areas.
• The company is dependent on FDA approval for the alternate manufacturing site supplement.
• The company is reliant on the successful commercialization of DefenCath.
• The company is subject to risks and uncertainties related to forward-looking statements.

Future Outlook

The company anticipates the commercial launch of DefenCath in outpatient settings in July 2024 and expects to receive FDA feedback on an updated development plan for DefenCath in TPN and pediatric study requirements by the end of the second quarter of 2024. They also anticipate approval of the supplement to add Siegfried Hameln as an alternate manufacturing site by the end of 2024.

Management Comments

• Joe Todisco, CorMedix CEO, stated, 'I am excited about the Company's recent progress as we have officially transitioned to a commercial stage organization.'
• Joe Todisco also mentioned, 'In only a few weeks of inpatient deployment we have received meaningful interest in scheduling DefenCath for formulary review at various institutions, and we look forward to additional progress in the coming months.'

Industry Context

This announcement reflects CorMedix's transition from a development-stage company to a commercial entity, with the launch of DefenCath. The receipt of TDAPA is a positive development for reimbursement. The company is competing in the market for therapies to prevent catheter-related bloodstream infections (CRBSI).

Comparison to Industry Standards

• CorMedix's transition to a commercial stage company is similar to other biopharmaceutical companies that have recently received FDA approval for their lead products.
• The 98% increase in SG&A expenses is typical for a company launching a new product, as it involves significant investment in sales and marketing.
• The decrease in R&D expenses is also expected as the company shifts focus from development to commercialization.
• The securing of a 5-year commercial supply contract with ARC Dialysis is a positive step, similar to other companies establishing distribution channels for their products.
• The receipt of TDAPA is a significant advantage, as it provides additional reimbursement for DefenCath, which is similar to other companies receiving favorable reimbursement decisions for their products.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and operating expenses.
• Employees may be impacted by the company's transition to a commercial stage organization.
• Customers may benefit from the availability of DefenCath.
• Suppliers may benefit from the increased demand for DefenCath.
• Creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue the commercial launch of DefenCath in the inpatient setting.
• The company will prepare for the outpatient launch of DefenCath in July 2024.
• The company will engage with customers regarding the potential to implement DefenCath as a preventative measure.
• The company will await FDA feedback on the updated development plan for DefenCath in TPN and pediatric study requirements.
• The company will await FDA approval of the supplement to add Siegfried Hameln as an alternate manufacturing site.

Key Dates

Keywords

DefenCath, commercial launch, TDAPA, biopharmaceutical, financial results, operating expenses, FDA, catheter lock, hemodialysis, CRBSI